Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(20 sites)
United States
City of Hope, Duarte, California University of California Los Angeles (UCLA) Medical Center, Santa Monica, California Norton Cancer Institute, Louisville, Kentucky Massachusetts General Hospital, Boston, Massachusetts Harvard Medical School - Beth Israel Deaconess Medical Center, Boston, Massachusetts Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey NYU Langone Health Perlmutter Cancer Center, New York, New York Icahn School of Medicine at Mount Sinai, New York, New York UT Southwestern, Dallas, Texas France
CHU de Bordeaux, Talence, New Aquitaine Hopital Saint Louis, Paris Gustave Roussy, Villejuif, Île-de-France Region Netherlands
Erasmus Medical Center Rotterdam, Rotterdam, South Holland Amsterdam University Medical Centre, location AMC, Amsterdam Spain
Hospital Vall d'Hebron, Barcelona University Hospital and Research Institute, Madrid United Kingdom
Royal Cornwall Hospitals NHS Trust, Truro, Cornwall Southampton General Hospital, Southampton, Hampshire Western General Hospital, Edinburgh, Scotland The Christie NHS Foundation Trust, Manchester